المؤلفون: Johannes Tröger, Ebru Baykara, Jian Zhao, Daphne ter Huurne, Nina Possemis, Elisa Mallick, Simona Schäfer, Louisa Schwed, Mario Mina, Nicklas Linz, Inez Ramakers, Craig Ritchie

المصدر: Digital Biomarkers, Vol 6, Iss 3, Pp 107-116 (2022)

مصطلحات موضوعية: mild cognitive impairment, digital biomarker, speech biomarker, dementia, speech analysis, clinical trials, Biology (General), QH301-705.5

الوصف: Introduction: Progressive cognitive decline is the cardinal behavioral symptom in most dementia-causing diseases such as Alzheimer’s disease. While most well-established measures for cognition might not fit tomorrow’s decentralized remote clinical trials, digital cognitive assessments will gain importance. We present the evaluation of a novel digital speech biomarker for cognition (SB-C) following the Digital Medicine Society’s V3 framework: verification, analytical validation, and clinical validation. Methods: Evaluation was done in two independent clinical samples: the Dutch DeepSpA (N = 69 subjective cognitive impairment [SCI], N = 52 mild cognitive impairment [MCI], and N = 13 dementia) and the Scottish SPeAk datasets (N = 25, healthy controls). For validation, two anchor scores were used: the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating (CDR) scale. Results: Verification: The SB-C could be reliably extracted for both languages using an automatic speech processing pipeline. Analytical Validation: In both languages, the SB-C was strongly correlated with MMSE scores. Clinical Validation: The SB-C significantly differed between clinical groups (including MCI and dementia), was strongly correlated with the CDR, and could track the clinically meaningful decline. Conclusion: Our results suggest that the ki:e SB-C is an objective, scalable, and reliable indicator of cognitive decline, fit for purpose as a remote assessment in clinical early dementia trials.

وصف الملف: electronic resource

العلاقة: https://www.karger.com/Article/FullText/526471Test; https://doaj.org/toc/2504-110XTest

الوصول الحر: https://doaj.org/article/d715274c09c14aa5807f9200f2c82a8fTest

المؤلفون: Simona, Schäfer, Elisa, Mallick, Louisa, Schwed, Alexandra, König, Jian, Zhao, Nicklas, Linz, Timothy Hadarsson, Bodin, Johan, Skoog, Nina, Possemis, Daphne, Ter Huurne, Anna, Zettergren, Silke, Kern, Simona, Sacuiu, Inez, Ramakers, Ingmar, Skoog, Johannes, Tröger

المساهمون: RS: MHeNs - R3 - Neuroscience, Basic Neuroscience 2, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychology 1, Psychology 2

المصدر: Journal of Alzheimer's Disease, 91(3), 1165-1171. IOS Press

مصطلحات موضوعية: Psychiatry and Mental health, Clinical Psychology, General Neuroscience, General Medicine, Geriatrics and Gerontology

الوصف: BACKGROUND: Modern prodromal Alzheimer's disease (AD) clinical trials might extend outreach to a general population, causing high screen-out rates and thereby increasing study time and costs. Thus, screening tools that cost-effectively detect mild cognitive impairment (MCI) at scale are needed.OBJECTIVE: Develop a screening algorithm that can differentiate between healthy and MCI participants in different clinically relevant populations.METHODS: Two screening algorithms based on the remote ki:e speech biomarker for cognition (ki:e SB-C) were designed on a Dutch memory clinic cohort (N = 121) and a Swedish birth cohort (N = 404). MCI classification was each evaluated on the training cohort as well as across on the unrelated validation cohort.RESULTS: The algorithms achieved a performance of AUC 0.73 and AUC 0.77 in the respective training cohorts and AUC 0.81 in the unseen validation cohort.CONCLUSION: The results indicate that a ki:e SB-C based algorithm robustly detects MCI across different cohorts and languages, which has the potential to make current trials more efficient and improve future primary health care.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::309dee186fd0b3643ecb8375d6ea4d0fTest
https://doi.org/10.3233/jad-220762Test

المؤلفون: Fabian Kern, Tobias Fehlmann, Christina Backes, Nadja Grammes, Kendall Van Keuren-Jensen, Eckart Meese, Louisa Schwed, Jeffrey Solomon, David Craig, Andreas Keller

المصدر: Nucleic Acids Research

مصطلحات موضوعية: AcademicSubjects/SCI00010, Breast Neoplasms, Computational biology, Biology, MiRBase, Workflow, Set (abstract data type), Mice, 03 medical and health sciences, Annotation, 0302 clinical medicine, Software, Genetics, Animals, Humans, Carcinoma, Renal Cell, 030304 developmental biology, computer.programming_language, 0303 health sciences, Application programming interface, business.industry, Parkinson Disease, Python (programming language), Kidney Neoplasms, MicroRNAs, 030220 oncology & carcinogenesis, Web Server Issue, Disease Progression, Female, business, computer, Biomarkers, Workflow management system

الوصف: Gene set enrichment analysis has become one of the most frequently used applications in molecular biology research. Originally developed for gene sets, the same statistical principles are now available for all omics types. In 2016, we published the miRNA enrichment analysis and annotation tool (miEAA) for human precursor and mature miRNAs. Here, we present miEAA 2.0, supporting miRNA input from ten frequently investigated organisms. To facilitate inclusion of miEAA in workflow systems, we implemented an Application Programming Interface (API). Users can perform miRNA set enrichment analysis using either the web-interface, a dedicated Python package, or custom remote clients. Moreover, the number of category sets was raised by an order of magnitude. We implemented novel categories like annotation confidence level or localisation in biological compartments. In combination with the miRBase miRNA-version and miRNA-to-precursor converters, miEAA supports research settings where older releases of miRBase are in use. The web server also offers novel comprehensive visualizations such as heatmaps and running sum curves with background distributions. We demonstrate the new features with case studies for human kidney cancer, a biomarker study on Parkinson’s disease from the PPMI cohort, and a mouse model for breast cancer. The tool is freely accessible at: https://www.ccb.uni-saarland.de/mieaa2Test.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e695c9e997a6bacfd256eeb91e171dTest
https://doi.org/10.1093/nar/gkaa309Test